Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Accumulated Expenses (2021 - 2025)

Historic Accumulated Expenses for Coeptis Therapeutics Holdings (COEPW) over the last 5 years, with Q3 2025 value amounting to $210892.0.

  • Coeptis Therapeutics Holdings' Accumulated Expenses fell 7158.56% to $210892.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $210892.0, marking a year-over-year decrease of 7158.56%. This contributed to the annual value of $736884.0 for FY2024, which is 3254.5% up from last year.
  • According to the latest figures from Q3 2025, Coeptis Therapeutics Holdings' Accumulated Expenses is $210892.0, which was down 7158.56% from $416209.0 recorded in Q2 2025.
  • Coeptis Therapeutics Holdings' Accumulated Expenses' 5-year high stood at $742201.0 during Q3 2024, with a 5-year trough of $181998.0 in Q4 2022.
  • Its 5-year average for Accumulated Expenses is $471078.1, with a median of $491235.0 in 2023.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 20547.04% in 2023, then plummeted by 7158.56% in 2025.
  • Over the past 5 years, Coeptis Therapeutics Holdings' Accumulated Expenses (Quarter) stood at $199126.0 in 2021, then fell by 8.6% to $181998.0 in 2022, then skyrocketed by 205.47% to $555950.0 in 2023, then surged by 32.55% to $736884.0 in 2024, then plummeted by 71.38% to $210892.0 in 2025.
  • Its Accumulated Expenses was $210892.0 in Q3 2025, compared to $416209.0 in Q2 2025 and $602447.0 in Q1 2025.